| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 000 | 5 | NIH | 11/17/2023 | $0 |
| | 2024 | 2022 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 001 | 5 | NIH | 1/26/2024 | $0 |
| | 2024 | 2022 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 003 | 5 | NIH | 8/7/2024 | $0 |
| | 2024 | 2022 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 002 | 5 | NIH | 3/11/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$105,651 ) |
| | 2023 | 2022 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 001 | 5 | NIH | 2/2/2023 | $0 |
| | 2023 | 2022 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 002 | 5 | NIH | 6/2/2023 | $0 |
| | 2023 | 2022 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 003 | 5 | NIH | 9/8/2023 | $0 |
| | 2023 | 2022 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 000 | 5 | NIH | 10/27/2022 | $0 |
| | 2023 | 2019 | ACCESS TO ADVANCED HEALTH INSTITUTE | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3797 | KING | USA | R01AI132634 | High Content Screening of Mycobacterium Tuberculosis | 000 | 3 | NIH | 10/11/2022 | -$105,651 |
|
| Issue Date FY: 2022 ( Subtotal = $786,095 ) |
| | 2022 | 2022 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 002 | 5 | NIH | 1/25/2022 | $786,095 |
| | 2022 | 2022 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 003 | 5 | NIH | 9/9/2022 | $0 |
| | 2022 | 2021 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 000 | 4 | NIH | 1/4/2022 | $0 |
| | 2022 | 2021 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 001 | 4 | NIH | 1/6/2022 | $0 |
| | 2022 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | F32AI136371 | Development of a novel replicating viral RNA vaccine platform | 001 | 2 | NIH | 4/22/2022 | $0 |
| | 2022 | 2018 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | F32AI136371 | Development of a novel replicating viral RNA vaccine platform | 000 | 1 | NIH | 4/22/2022 | $0 |
| | 2022 | 2015 | Infectious Disease Research Institute | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | IDSEP140022 | Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under-Resourced Nations | 13 | 2 | ASPR | 9/26/2022 | $0 |
| | 2022 | 2015 | Infectious Disease Research Institute | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | IDSEP140022 | Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under-Resourced Nations | 12 | 2 | ASPR | 6/13/2022 | $0 |
| | 2022 | 2014 | Infectious Disease Research Institute | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | IDSEP140022 | Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under-Resourced Nations | 12 | 2 | ASPR | 6/13/2022 | $0 |
| | 2022 | 2014 | Infectious Disease Research Institute | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | IDSEP140022 | Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under-Resourced Nations | 13 | 2 | ASPR | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $26,772 ) |
| | 2021 | 2021 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 002 | 4 | NIH | 9/1/2021 | $0 |
| | 2021 | 2021 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 000 | 4 | NIH | 3/11/2021 | $833,113 |
| | 2021 | 2021 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 001 | 4 | NIH | 7/27/2021 | $833,113 |
| | 2021 | 2021 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 001 | 4 | NIH | 7/27/2021 | -$833,113 |
| | 2021 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI125160 | Immunotherapy to prevent drug-resistant tuberculosis | 001 | 4 | NIH | 4/6/2021 | -$802,216 |
| | 2021 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R21AI142267 | Vaccine-based immunotherapy as an adjunct to drug treatment against NTM | 000 | 1 | NIH | 6/3/2021 | $0 |
| | 2021 | 2018 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI125160 | Immunotherapy to prevent drug-resistant tuberculosis | 000 | 3 | NIH | 4/6/2021 | -$20,388 |
| | 2021 | 2018 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI132634 | High Content Screening of Mycobacterium Tuberculosis | 000 | 2 | NIH | 4/15/2021 | $52,825 |
| | 2021 | 2018 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI129360 | The role of Esx-3 in mediating drug resistance | 000 | 1 | NIH | 3/4/2021 | -$36,562 |
|
| Issue Date FY: 2020 ( Subtotal = -$975,451 ) |
| | 2020 | 2020 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 000 | 3 | NIH | 3/19/2020 | $848,166 |
| | 2020 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI129360 | The role of Esx-3 in mediating drug resistance | 000 | 2 | NIH | 5/22/2020 | -$435,250 |
| | 2020 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | F32AI136371 | Development of a novel replicating viral RNA vaccine platform | 000 | 2 | NIH | 5/26/2020 | $0 |
| | 2020 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI132634 | High Content Screening of Mycobacterium Tuberculosis | 000 | 3 | NIH | 5/15/2020 | -$635,802 |
| | 2020 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI125160 | Immunotherapy to prevent drug-resistant tuberculosis | 000 | 4 | NIH | 5/28/2020 | -$535,796 |
| | 2020 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R21AI142267 | Vaccine-based immunotherapy as an adjunct to drug treatment against NTM | 000 | 1 | NIH | 5/28/2020 | -$216,769 |
| | 2020 | 2018 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R21AI124132 | Development of a Chikungunya Vaccine Candidate | 000 | 2 | NIH | 2/4/2020 | $0 |
| | 2020 | 2018 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R21AI124132 | Development of a Chikungunya Vaccine Candidate | 001 | 2 | NIH | 4/22/2020 | $0 |
| | 2020 | 2015 | Infectious Disease Research Institute | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | IDSEP140022 | Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under-Resourced Nations | 10 | 2 | ASPR | 12/20/2019 | $0 |
| | 2020 | 2015 | Infectious Disease Research Institute | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | IDSEP140022 | Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under-Resourced Nations | 11 | 2 | ASPR | 12/20/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $3,561,696 ) (Continued on the next page) |
| | 2019 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI129360 | The role of Esx-3 in mediating drug resistance | 000 | 2 | NIH | 7/29/2019 | $435,250 |
| | 2019 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | F32AI136371 | Development of a novel replicating viral RNA vaccine platform | 000 | 2 | NIH | 1/31/2019 | $61,610 |
| | 2019 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI132634 | High Content Screening of Mycobacterium Tuberculosis | 000 | 3 | NIH | 6/18/2019 | $635,802 |
| | 2019 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI125160 | Immunotherapy to prevent drug-resistant tuberculosis | 000 | 4 | NIH | 4/23/2019 | $1,338,012 |
| | 2019 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R21AI142267 | Vaccine-based immunotherapy as an adjunct to drug treatment against NTM | 000 | 1 | NIH | 5/14/2019 | $261,150 |
| | 2019 | 2019 | INFECTIOUS DISEASE RESEARCH INSTITUTE | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R01AI135673 | Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | 000 | 2 | NIH | 12/3/2018 | $856,636 |
|
